ACSS2 inhibition boosts cabozantinib activity in liver cancer models
Preclinical hepatocellular carcinoma models showed that blocking ACSS2 or autophagy enhanced cabozantinib’s antitumor activity by disrupting a TFEB-linked protective response.
Preclinical hepatocellular carcinoma models showed that blocking ACSS2 or autophagy enhanced cabozantinib’s antitumor activity by disrupting a TFEB-linked protective response.
New research reveals that the cellular recycling protein p97/VCP directly regulates the autophagic degradation of androgen-binding protein in Sertoli cells, ...
Researchers have discovered that the calcium-rich bone microenvironment drives chemotherapy tolerance in osteosarcoma through an ORAI3–Ca²⁺–NFAT4–PINK1 mitophagy axis that can ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine